Publications by authors named "Sonja Jansen-Skoupy"
Article Synopsis
- The ELIMINATE project aimed to reconnect individuals in Eastern Austria with previously documented hepatitis C virus (HCV) infections to medical care, supporting global elimination goals set by the WHO.
- Researchers reviewed lab records from 2008 to 2020, identifying 5,695 individuals, but faced challenges such as 34% having died and 13% lacking contact information.
- Ultimately, they successfully contacted 617 individuals, leading to a 64.3% treatment initiation rate, and confirmed an HCV cure in 326 people, demonstrating the effectiveness of targeted outreach strategies in addressing HCV.
Article Synopsis
- The study aimed to use existing laboratory records to identify and treat individuals with hepatitis C virus (HCV) viremia, assisting in broader global elimination efforts.
- Out of 22,682 individuals who tested for HCV-RNA, 6006 had detectable viremia; barriers like invalid contact information hindered follow-up, but efforts led to successful treatment initiation in some.
- This interim report from the ELIMINATE project highlights the potential of systematic screening and recall, identifying a significant number of people previously lost to care who began antiviral treatment.
Immunocompromised patients experience reduced vaccine effectiveness and are at higher risk for coronavirus disease 19 (COVID-19) death. Pre-exposure prophylaxis (PrEP) aims to protect these patients. So far, only tixagevimab/cilgavimab is authorized for use as PrEP.
View Article and Find Full Text PDFBackground: Point-of-care antigen tests (AgTs) for the detection of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) enable the rapid testing of infected individuals and are easy-to-use. However, there are few studies evaluating their clinical use.
Objective: The present study aimed to evaluate and compare the clinical performance characteristics of various commercial SARS-CoV-2 AgTs.
Background: Chronic kidney disease patients show a high mortality in cases of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV‑2) infection. Thus, information on the sero-status of nephrology personnel might be crucial for patient protection; however, limited information exists about the presence of SARS-CoV‑2 antibodies in asymptomatic individuals.
Methods: We examined the seroprevalence of SARS-CoV‑2 IgG and IgM antibodies among healthcare workers of a tertiary care kidney center during the the first peak phase of the corona virus disease 2019 (COVID-19) crisis in Austria using an orthogonal test strategy and a total of 12 commercial nucleocapsid protein or spike glycoprotein-based assays as well as Western blotting and a neutralization assay.
Background: Reference intervals provided by diagnostic test manufacturers should be transferred to clinical laboratories after validation. Although protocols exist, laboratories rarely perform and report on results of validation studies.
Methods: We validated reference intervals (RIs) of 87 analytes on a Cobas 8000 platform according to standards published by the Clinical and Laboratory Standards Institute (CLSI).